[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Adams G, Zekri J, Wong H, Walking J, Green JA: Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy? BJOG; 2010 Nov;117(12):1459-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?
  • OBJECTIVE: To evaluate the clinical benefit and toxicity of two regimens; single agent carboplatin (C) and a carboplatin/paclitaxel (CP) combination in early epithelial ovarian cancer.
  • SETTING: Single cancer centre serving a population of 2.1 million in the northwest of England.
  • POPULATION: All women treated with adjuvant chemotherapy for International Federation of Obstetrics and Gynecology stage Ia-IIc ovarian cancer between 2002 and 2005.
  • Details of the surgery performed, performance status (PS), tumour histology, stage, grade, intended chemotherapy, chemotherapy received, acute and late toxicity, relapse and death were all recorded.
  • For the subgroup with stage I disease and good PS (0/1) 5-year OS was 80% (59-100%) for C and 79% (63-95%) for CP; P = 1.0.
  • For those with stage 2 disease, 5-year OS was 29% (95% CI 0-62%) for C and 63% (95% CI 44-82%) for CP; P = 0.025.
  • CONCLUSIONS: Combination therapy is administered more often than carboplatin; especially in those with younger age, better PS and nonmucinous histology.
  • Recurrence and death rates were similar with both treatments.
  • Well-designed trials are needed to identify the optimum chemotherapy regimen in this group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors Journal compilation © RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology.
  • [CommentIn] BJOG. 2010 Nov;117(12):1441-3 [20960600.001]
  • (PMID = 20560942.001).
  • [ISSN] 1471-0528
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Riedinger JM: [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study]. Bull Cancer; 2007 Mar;94(3):287-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
  • [Transliterated title] Valeur pronostique de la demi-vie du CA125 et de sa normalisation précoce au cours de la chimiothérapie des tumeurs avancées de l'ovaire: résultats d'une étude multicentrique française.
  • This multicentric study was performed in 494 patients with advanced epithelial ovarian cancer in order to assess the predictive and prognostic value of CA125 half-life and CA125 time to normalization during induction chemotherapy in these patients.
  • For 494 stage IIC-IV patients, 397 relapsed (80.4 %) and 382 died (77.3 %) from cancer during follow time (median = 34 months ; range : 3-215 months).
  • CA 125 half-life and time needed for CA125 normalization had an univariate prognostic value for overall survival (OS) (p < 0.0001 for both).
  • Conclusion : Among well-established prognostic factors in ovarian cancers, CA 125 half-life and CA125 time to normalization were independent prognostic factors for both achievement of pathological complete response and survival.
  • [MeSH-major] CA-125 Antigen / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371771.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


3. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A: Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res; 2007 Jan-Feb;27(1B):611-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome.
  • BACKGROUND: The prognostic significance of age in ovarian cancer has not been clarified.
  • We investigated the characteristics of ovarian cancer presenting in ages > 70 years and assessed the prognostic significance of advanced age.
  • PATIENTS AND METHODS: Four hundred and fifty-three patients with stage IIC-IV ovarian cancer (age>70 years n=106 [23%]), treated postoperatively with platinum-based chemotherapy were retrospectively reviewed.
  • Toxicity from chemotherapy was similar between the two age groups, but the relative dose intensity of paclitaxel was lower among elderly patients.
  • CONCLUSION: The worse outcome of ovarian cancer in elderly patients may be attributed to other associated adverse prognostic factors, but advanced age was not an independent prognostic factor.
  • [MeSH-major] Epithelial Cells / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Anemia / chemically induced. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348450.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B: The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer; 2002 May-Jun;12(3):265-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
  • Epithelial ovarian cancer is one of the major causes of death among women.
  • The increasing knowledge about molecular events involved in the early stages of ovarian tumorigenesis may provide the basis for management in the future.
  • In a series of 109 patients with epithelial carcinomas in FIGO stages IA-IIC, a number of clinicopathologic prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to the biologic factors p53, bcl-2, and bax, which are important regulators of apoptosis.
  • All the patients received adjuvant chemotherapy after the primary surgery.
  • Univariate analysis showed that expression of p53 was significantly associated with tumor grade (P = 0.014), probability of persistent disease (P = 0.016), and cancer-specific survival rate (P = 0.007).
  • The bax status was not a prognostic factor, but the combined p53-bax expression showed an association with FIGO stage (P = 0.014), tumor grade (P = 0.034), persistent disease (P = 0.006), and risk of dying due to the disease (P = 0.039).
  • In a multivariate Cox analysis, tumor grade (P = 0.014), and p53 status (P = 0.020) were independent and significant prognostic factors with regard to the cancer-specific survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma / drug therapy. Carcinoma / metabolism. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Survival Rate. bcl-2-Associated X Protein

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060448.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J: An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol; 2009 Apr;113(1):63-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
  • OBJECTIVES: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery.
  • METHODS: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease <1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol.
  • Patients received intravenous (IV) docetaxel 75 mg/m(2) and IP cisplatin 75-100 mg/m(2) on day 1, followed by IP paclitaxel 60 mg/m(2) on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy.
  • Charts were abstracted for demographic, chemotherapy, and toxicity-related data.
  • RESULTS: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%).
  • Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered.
  • There was one treatment-related death.
  • Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related.
  • CONCLUSIONS: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible.
  • This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens.
  • Port-related complications were a leading cause of IP chemotherapy discontinuation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Amifostine / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Outpatients. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Pilot Projects. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201457.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH: Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):101-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy.
  • This study reviews the clinical outcome and prognosis of patients with malignant mixed müllerian tumors (MMMTs) of the ovary treated with optimal cytoreductive surgery, leaving no residual disease, and platinum-based chemotherapy.
  • Ten patients diagnosed with MMMT of the ovary after complete surgical staging from February 1993 to February 2004 at Asan Medical Center in Korea were studied retrospectively.
  • Seven patients received ifosfamide/cisplatin chemotherapy, and the remaining three patients received other platinum-based combination chemotherapy.
  • Demographic data, pathologic findings, treatments, and survival time were reviewed.
  • Of the ten patients, two were scored at FIGO stage IIC, seven were at stage IIIC, and one was at stage IV.
  • The median survival time of all ten patients was 46 months.
  • Platinum-based combination chemotherapy after optimal cytoreductive surgery may be effective in the treatment of ovarian MMMT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Probability. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Taïeb S, Bonodeau F, Leblanc é, Vennin P, Fournier C, Besson P: [Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma]. Bull Cancer; 2000 Mar;87(3):265-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma].
  • [Transliterated title] Valeur prédictive du scanner abdomino-pelvin pour la chirurgie optimale des carcinomes de l'ovaire.
  • Some patients underwent laparoscopy without optimal debulking surgery as initial treatment for advanced ovarian carcinoma.
  • Neoadjuvant chemotherapy is a new therapeutic approach.
  • The purpose was to access the ability of preoperative abdominopelvic CT to predict success of debulking surgery for ovarian carcinoma: less than 1 cm of residual tumor size after initial surgery.
  • We reviewed 39 patients (2 stages Ic, 1 stage IIc, 22 stages III and 14 stages IV) operated on for ovarian carcinoma between January 1992 and December 1997.
  • These results allowed us to determine wich CT criteria were accurate and reproducible to be a helpfull for therapeutic choice and to avoid laparotomy without optimal surgery.
  • [MeSH-major] Ovarian Neoplasms / radiography. Ovarian Neoplasms / surgery. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Observer Variation. Predictive Value of Tests. Prospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10779815.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


8. Yan X, An N, Jiang GQ, Gao M, Gao YN: [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi; 2008 Apr;30(4):298-301
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
  • OBJECTIVE: To compare the survival of patients with stage IIc or IV epithelial ovarian cancer treated either with neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery or primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy.
  • METHODS: The clinical and pathological data of 160 patients with stage IIIc or IV epithelial ovarian cancer diagnosed pathologically between 1997 and 2005 were retrospectively reviewed.
  • Forty-two patients were treated with NAC followed by cytoreductive surgery (NAC group) and 118 patients with PCS followed by adjuvant chemotherapy (PCA group).
  • No significant difference was observed between the NAC group and PCS group in operating time, intra-operative blood loss and units of blood-transfusion (P > 0.05).
  • CONCLUSION: Neoadjuvant chemotherapy followed by cytoreductive surgery can improve the rate of optimal cytoreductive surgery for the patients with stage IIIc or IVepithelial ovarian cancer, but this regimen may neither reduce the recurrent rate nor prolong the survival when compared with the patients treated with primary cytoreductive surgery followed by adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / drug therapy. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788637.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol; TP protocol
  •  go-up   go-down


9. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, Dalifard I, Hacene K, Pichon MF: CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol; 2006 Aug;17(8):1234-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study.
  • BACKGROUND: CA 125 assays enable treatment-response monitoring in ovarian cancer.
  • PATIENTS AND METHODS: A multicentric study of CA 125 kinetics under induction chemotherapy was performed in 631 patients.
  • Nadir CA 125 concentration and time to nadir were also studied.
  • RESULTS: For 553 stage IIC-IV patients, 459 (83.0%) relapsed and 444 (80.3%) died from cancer.
  • Median (range) follow up time was 32 months (2-214 months).
  • Median (range) for CA 125 kinetics were: 263 kU/l (5-52000 kU/l) before 1st course, 15.8 days (4.5-417.9 days) for CA 125 half-life, 16 kU/l (3-2610 kU/l) for nadir and 85 days (0-361 days) for time to nadir.
  • Pre-chemotherapy CA 125, its half-life, nadir concentration and time to nadir all had a univariate prognostic value for DFS and OS (P<0.0001).
  • In Cox models, CA 125 half-life, residual tumour (P<0.0001 for both), nadir concentration (P=0.0002) and stage (P=0.0118) were the most powerful prognostic factors for DFS.
  • CONCLUSION: Among well-established prognostic factors in ovarian cancers, CA 125 half-life and nadir concentration bear a strong and independent prognostic value.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766592.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


10. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, Cosio S, Frassi E, LaPresa MT, Fuso L, Cristofani R: Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol; 2005 Feb 1;23(4):751-8
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
  • PURPOSE: To assess whether the interval from primary surgery to the start of taxane- plus platinum-based chemotherapy has any impact on the clinical outcome of advanced ovarian cancer patients.
  • PATIENTS AND METHODS: The study was conducted on 313 patients who underwent surgery followed by taxane- plus platinum-based chemotherapy.
  • RESULTS: The 25%, 50%, and 75% quantiles of intervals from surgery to the start of chemotherapy were 11, 21, and 31 days, respectively.
  • Residual disease (< or = 1 v > 1 cm; P < .0001) and ascites (absent v present; P = .003) were independent predictive factors for achieving a complete response, whereas residual disease (P = .001) and stage (IIc to III v IV; P = .04) were independent prognostic variables for survival.
  • Conversely, statistical analyses failed to detect significant differences in complete response rates and survival among patients with an interval from surgery to chemotherapy shorter than 11 days, 12 to 21 days, 22 to 31 days, and longer than 31 days.
  • CONCLUSION: The interval from surgery to the start of taxane- plus platinum-based chemotherapy seems to have neither a predictive value for response to treatment nor a prognostic relevance for survival of advanced ovarian cancer patients.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 1;23(4):665-6 [15613693.001]
  • (PMID = 15613698.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF: Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol; 2008 May;109(2):194-8
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
  • BACKGROUND: CA 125 assays enable treatment-response monitoring in ovarian cancer.
  • METHODS: A multicentric study of CA 125 kinetics under paclitaxel/platinum-based chemotherapy was performed in 130 stage IIc-IV patients.
  • RESULTS: During a median follow-up time of 29 months (range 5-106 months), 111 patients (85%) relapsed and 94 (72%) died from ovarian cancer.
  • Patients were split into 4 groups according to their pattern of CA 125 decrease: non-assessable half-life because of a low pre-chemotherapy CA 125 level (n=38), half-life < or = 14 days and mono-exponential CA 125 decay (n=18), half-life < or = 14 days and bi-exponential CA 125 decay (n=21), and half-life > 14 days (n=53).
  • In Cox models, nadir concentration, residual tumour volume and number of chemotherapy courses were found to be independent prognostic factors for DFS and OS.
  • CONCLUSION: Characteristics of CA 125 kinetics during first line paclitaxel/platinum chemotherapy have a strong and independent prognostic value.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. CA-125 Antigen / blood. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Platinum / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329083.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; 49DFR088MY / Platinum; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Colombo N, Fanucchi A, Chiudinelli F, Lapresa M, Maria Ferrero A: Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study. Gynecol Oncol; 2005 Jul;98(1):118-23
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
  • OBJECTIVE: The aim of this retrospective multicenter study was to assess whether the pre-chemotherapy hemoglobin levels have any impact on the clinical outcome of patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen.
  • METHODS: The study was conducted on 315 patients who underwent initial surgery followed by taxane/platinum-based chemotherapy for FIGO stage IIc-IV epithelial ovarian cancer.
  • RESULTS: The 25%, 50%, and 75% quantiles of hemoglobin levels before starting first-line chemotherapy were 10.2, 11.4, and 12.3 g/dl, respectively.
  • CONCLUSIONS: This investigation showed that hemoglobin levels before starting first-line taxane/platinum-based chemotherapy are not an independent prognostic factor for overall survival in patients with advanced epithelial ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemoglobins / metabolism. Ovarian Neoplasms / blood. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913740.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Deplanque G, Goupil A, Fabbro M, Levy E, Rixe O, Benettaib B, Cvitkovic E: Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results. J Clin Oncol; 2004 Jul 15;22(14_suppl):5075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): Preliminary results.
  • : 5075 Background: Despite the introduction of paclitaxel/platinum combinations in first line treatment of AOC, a small proportion of patients fail to respond.
  • METHODS: AOC pts with histologically proven stage IIc or IIIa-c after maximal debulking surgery (microscopic disease or macroscopic disease ≤2 cm) performed 2-7 weeks before study treatment start, received 175 mg/m<sup>2</sup> P, 3-hour intravenous infusion, followed by 130 mg/m<sup>2</sup> OXA, 2-hour intravenous infusion, every 3 weeks, on an outpatient basis, without G-CSF.
  • Pts with positive histology after second look surgery could receive up to 2 further cycles; pts with pathological complete response received no further treatment.
  • RESULTS: Between Aug 2001 and Jan 2003, 17 pts were entered in 9 centres (49 planned), 14 eligible, 3 ineligible (2 colorectal cancer with peritoneal presentation, 1 pre-treated with OXA/cisplatin/P).
  • Median age 59 years (range 40-68); Performance status 0/1/2: 10/3/1; histology serous: 11, other: 3; FIGO stage IIIb: 5, IIIc: 9; microscopic residual disease: 3, macroscopic: 11.
  • CONCLUSION: The OXA/P combination shows high antitumor activity and a safe toxicity profile in first-line treatment for AOC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. García-Velasco A, Hernando S, Mendiola C, Castellano D, Sánchez-Muñoz A, Del Val O, Manso L, Quintela M, Cortés-Funes H: Paclitaxel, cisplatin, and cyclophosphamide (PCC) first-line chemotherapy for advanced ovarian carcinoma: Long-term results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, cisplatin, and cyclophosphamide (PCC) first-line chemotherapy for advanced ovarian carcinoma: Long-term results of a phase II study.
  • : 5135 Background: Despite high responses to cisplatin-based combination chemotherapy, the overall survival rate for advanced ovarian cancer remains poor.
  • The combination of PCC as 1st-line treatment for ovarian cancer (OC) has significant activity with high primary response rates.
  • To evaluate long-term results and to assess prognostic factors which have an impact on overall survival we analysed the data from a prospective phase II trial of this treatment combination Methods: 54 patients with OC ( FIGO IIc n=9, IIIc the n=38, IV n=7) were treated between January 1997 and December 2000 with six cycles of P (175mg/m<sup>2</sup>), C (75mg/m<sup>2</sup>) and C (600mg/m<sup>2</sup>) after optimal (n=22) or suboptimal (n=32) debulking surgery.
  • Median age at treatment was 52 years.
  • CA 125 was elevated after surgery in 44 patients and at the end of chemotherapy in 6 patients.
  • A second laparotomy was performed after chemotherapy to 14 patients with macroscopic disease Results: Of 30 evaluable patients for response, 15 achieved a clinical complete response (50%), 12 a partial response (40%), and 3 disease stabilization (10%).
  • OS rate for FIGO IIIc-IV patients was 35%.
  • In a multivariate analysis, the only negative prognostic factors for survival were: FIGO stage IIIc-IV (p<0.04), suboptimal debulking surgery (p<0.001), and elevated CA 125 at the end of chemotherapy (p<0.05) Conclusions: Our study confirms the effectiveness of PCC regimen in the treatment of epithelial OC in the long term.
  • FIGO stage, extend of debulking surgery, and CA 125 at the end of chemotherapy, are independent prognostic factors for overall survival.
  • These long-term results support the conduct of randomised studies to determine the impact of this triplet in the treatment of advanced ovarian cancer No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tominaga E, Tsuda H, Arao T, Nishimura S, Chiyoda T, Nomura H, Kataoka F, Susumu N, Aoki D, Nishio K: Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of amplification of the 8q24 and 20q11-13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy.
  • : e16526 Background: The purpose of this study was to identify genes that predict the progression free survival (PFS) of advanced epithelial ovarian cancer (aEOC) receiving standard therapy.
  • Thirty three aEOC patients (stage IIc: 4, III: 19, IV: 10; serous adenocarcinoma: 21, endometrioid adenocarcinoma: 5, undifferentiated: 7) were included in this array study.
  • All cases received staging laparotomy, cytoreductive surgery, and adjuvant chemotherapy (carboplatin + paclitaxel) as primary therapy.
  • Finally, we focused on 8q24 and 20q11-13 loci, and confirmed array data using real-time quantitative PCR in 94 validation sets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960791.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA, AGO-Ovar/AIO, EBMT: Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol; 2007 Sep 20;25(27):4187-93
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
  • PURPOSE: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon.
  • A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome.
  • PATIENTS AND METHODS: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.
  • The median age was 50 years (range, 20 to 65 years) and International Federation of Gynecology and Obstetrics stage was IIb/IIc in 4%, III in 78%, and IV in 17%.
  • CONCLUSION: This is the first randomized trial comparing sequential HD versus standard dose chemotherapy in first-line treatment of patients with advanced ovarian cancer.
  • We observed no statistically significant difference in progression-free survival or OS and conclude that HD chemotherapy does not appear to be superior to conventional dose chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cyclophosphamide / administration & dosage. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Paclitaxel / administration & dosage. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Melphalan / administration & dosage. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4157-8 [17698802.001]
  • (PMID = 17698804.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  •  go-up   go-down


17. Riedinger JM, Bonnetain F, Basuyau JP, Eche N, Larbre H, Dalifard I, Wafflart J, Ricolleau G, Pichon MF: Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol; 2007 May;18(5):881-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.
  • BACKGROUND: CA 125 assays enable treatment response monitoring in ovarian cancer.
  • PATIENTS AND METHODS: This multicentric study was carried out to assess the prognostic value of the CA 125 change after the first and the second courses of induction chemotherapy (CT).
  • Of the 494 stage IIc-IV patients, 194 had a surgical second look, 397 (80.4%) relapsed and 382 (77.3%) died from cancer.
  • Median (range) follow-up time was 34 months (3-215 months).
  • CONCLUSION: Among well-established prognostic factors in ovarian cancers, the CA 125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2007 Nov;4(11):628-9 [17768412.001]
  • (PMID = 17301071.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


18. Ho CM, Cheng WF, Lin MC, Chen TC, Huang SH, Liu FS, Chien CC, Yu MH, Wang TY, Hsieh CY: Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer; 2010 Dec;20(9):1490-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
  • OBJECTIVES: The purpose of the study was to analyze negative versus positive immunoexpression of epithelial cadherin (E-cadherin) and p53 in patients with primary advanced ovarian clear cell adenocarcinoma (OCCA) and its significance in relation to clinical features, progression-free survival and overall survival (OS).
  • METHODS AND MATERIALS: Protein expression of E-cadherin and p53 was immunohistochemically evaluated in 61 OCCA patients with stages IIC to IV.
  • The clinical factors studied included stage, age, CA-125, residual tumors, and chemotherapy regimens.
  • The expected 5-year OS rate of OCCA treated with paclitaxel-based chemotherapy was significantly better than non-paclitaxel-based chemotherapy (40% vs 0%, P = 0.001).
  • The expected 5-year OS rate of those receiving paclitaxel-platinum chemotherapy was not significantly different from platinum-based chemotherapy for those with negative E-cadherin immunoexpression (P = 0.11).
  • The expected 5-year OS rate of those receiving paclitaxel-based chemotherapy was better than non-paclitaxel-based chemotherapy for those with positive E-cadherin immunoexpression (43% vs 0%, P = 0.01).
  • Paclitaxel-based chemotherapy and positive E-cadherin immunoexpression were 2 independent prognostic factors in OS of patients with OCCA (P = 0.01 and 0.04, respectively).
  • CONCLUSIONS: E-cadherin is a useful prognostic marker for OCCA patients, and paclitaxel-based chemotherapy can improve survival among patients with positive E-cadherin immunoreactivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Cadherins / metabolism. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119364.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Niimi S, Kiyokawa T, Takakura S, Ochiai K, Tanaka T: Recurrent small cell carcinoma of the ovary treated with docetaxel: A case report. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1944-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent small cell carcinoma of the ovary treated with docetaxel: A case report.
  • Multiagent chemotherapy for small cell carcinoma of the ovary (SCCO) may contribute to the prolonged survival of young women who are suffering from this disease, even in the advanced stage with remaining tumor, although the rarity of SCCO complicates the generalization of chemotherapy agents and operation methods for this disease.
  • A 24-year-old patient with SCCO FIGO stage IIC is alive after recurrences and chemotherapy including cisplatin + etoposide after the first operation and docetaxel for the second recurrence.
  • She is now doing well with no evidence of disease more than 4 years after the first operation and 2 years after docetaxel treatment.
  • This may be the first report describing the use of docetaxel that may be included in multiagent chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Small Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Taxoids / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Etoposide / therapeutic use. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009997.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol; 2002 Oct;87(1):8-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
  • OBJECTIVE: The initial clinical response to platinum is a major determinant of outcome for patients with ovarian cancer.
  • This retrospective study was undertaken to correlate the response and survival of newly diagnosed advanced ovarian cancer patients who received platinum-based therapy with in vitro drug response to cisplatin or carboplatin measured as percentage cell inhibition (PCI) in the in vitro Extreme Drug Resistance (EDR) assay.
  • METHODS: Outcomes for newly diagnosed ovarian cancer patients with tumor specimens submitted in a serial fashion for the EDR assay were studied.
  • EDR assay results for cisplatin and carboplatin were correlated with clinical outcome for 79 evaluable chemotherapy nai;ve cases who presented with advanced (stages IIC, III, and IV) ovarian cancer.
  • Stage IV and suboptimally debulked stage IIIc accounted for 16 cases, while 63 cases were optimally debulked Stage III/IIc.
  • All patients were treated with platinum-based combination chemotherapy at a single institution.
  • In vitro results for patient tumors were classified as low drug resistance (PCI > median), intermediate drug resistance [PCI between the median and 1 standard deviation (SD) below the median], or extreme drug resistance (PCI more than 1 SD below the median).
  • RESULTS: Median PFS was 6 months for the 17 cases exhibiting EDRP, compared to 24 months for the 62 cases exhibiting LDRP in vitro [relative risk (RR) 3.78, confidence intervals (CI) 1.82-7.83], adjusted for stage, debulking status, in vitro response to 3-OH-cyclophosphamide, and histological grade.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / pharmacology. Cisplatin / pharmacology. Cyclophosphamide / analogs & derivatives. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cohort Studies. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1XBF4E50HS / 4-hydroxycyclophosphamide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L: Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):26-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of hepatic metastasis in patients with ovarian cancer.
  • The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer.
  • From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari.
  • Twenty-nine patients identified included one having stage IIC, one stage IIIA, two stage IIIB, 17 stage IIIC, and eight stage IVB.
  • Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse.
  • The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients.
  • Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival.
  • Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Liver Neoplasms / diagnosis. Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670293.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Li B, Wu LY, Zhang WH, Li L, Ma SK, Liu LY: [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor]. Zhonghua Fu Chan Ke Za Zhi; 2004 May;39(5):334-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor].
  • OBJECTIVE: To study the clinical characteristics, treatment and prognostic factors of ovarian Setoli-Leydig cell tumor.
  • Nine of the tumors were stage Ia, 1 was stage IIc and 1 was stage IIIc.
  • Two patients suffered from breast cancer.
  • And 5 patients with poorly differentiated or stage II-III tumors were subjected to postoperational chemotherapy.
  • CONCLUSIONS: Ovarian Setoli-Leydig cell tumor has good prognosis.
  • Surgery alone is a currently acceptable treatment for patients with well-differentiated early stage tumors.
  • For patients with poorly differentiated or advanced tumors, postoperational chemotherapy seems to be necessary.
  • Conservative surgery should be the treatment of choice in young patients who need future fertility.
  • [MeSH-major] Ovarian Neoplasms. Sertoli-Leydig Cell Tumor
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196418.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Skirnisdóttir I, Sorbe B: Adjuvant radiotherapy in stage I-II epithelial ovarian cancer. Eur J Gynaecol Oncol; 2001;22(6):409-16
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy in stage I-II epithelial ovarian cancer.
  • OBJECTIVE: The purpose of this study was to assess the efficacy and side-effects of abdominopelvic irradiation applied as adjuvant postoperative therapy in early stage ovarian carcinomas.
  • METHODS: From 1 January 1988 to 31 December 1993, 113 patients with FIGO stage IA-IIC epithelial ovarian carcinoma were treated with postoperative radiotherapy.
  • The dose of specification was 20 Gy to the upper part of the abdominal cavity and 40 Gy to the lower part of the abdomen and the pelvic region.
  • The overall 5-year survival rate for the complete series was 69% and the cancer-specific survival rate was 72%.
  • Early radiation reactions of any type were noted in 93% of the cases and, in 11%, discontinuation of radiotherapy was necessary.
  • CONCLUSIONS: Adjuvant abdominopelvic radiotherapy is one option among others (e.g. various types of chemotherapy or no further treatment) in primary treatment of early stage ovarian carcinoma.
  • The optimal adjuvant therapy for this group of patients is not known today and further prospective and randomized studies are needed.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / radiotherapy. Ovarian Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874070.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Friedlander M, Buck M, Wyld D, Findlay M, Fitzharris B, De Souza P, Davies T, Kalimi G, Allan S, Perez D, Harnett P: Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):350-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer.
  • The aim of this exploratory phase II study was to evaluate sequential chemotherapy with carboplatin followed by gemcitabine-paclitaxel combination in chemonaive patients with advanced ovarian cancer.
  • The primary objective was to evaluate time to progressive disease (TTPD); secondary objectives included the evaluation of 1- and 3-year survival, response rates, and toxicity.
  • Following initial debulking surgery or biopsy, patients with FIGO stage IIC-IV disease received four cycles of carboplatin area under the curve (AUC) 6 (day 1) every 21 days, followed by four cycles of gemcitabine 1000 mg/m(2) (days 1 and 8) and paclitaxel 175 mg/m(2) (day 8) every 21 days.
  • Median TTPD was 13.8 months (95% CI, 11.6-21.0 months), and median survival time was 31.2 months (95% CI, 25.2-39.6 months).
  • Of the 43 evaluable patients, most (95.3%) of them achieved a CA-125 marker response based on Gynecologic Cancer Intergroup (GCIG) definition.
  • The sequential approach of carboplatin followed by gemcitabine-paclitaxel as first-line treatment for patients with ovarian cancer is feasible and well tolerated, and depending upon the findings from other major trials, it may merit further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Middle Aged. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362312.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Rim SY, Kim SM, Choi HS: Malignant transformation of ovarian mature cystic teratoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):140-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of ovarian mature cystic teratoma.
  • There have been few studies concerning the clinical pathology of malignant transformation arising in ovarian mature cystic teratoma (MCT).
  • From November 1992 to December 2002, 11 patients with malignant transformation arising in ovarian MCT were treated at Department of Obstetrics and Gynecology in Chonnam National University Hospital.
  • Demographic characteristics, symptoms, signs, stage, mode of therapy, and results of follow-up were reviewed retrospectively.
  • There were 11 cases of the malignant transformation of ovarian MCT out of 637 cases of MCT (1.7%).
  • Histologically, 7 out of the 11 cases were squamous cell carcinoma (63.7%).
  • As for the stage of disease, eight cases were in stage IA (72.7%), and the other three cases were in stage IC, IIB, and IIC, respectively.
  • All the patients had surgery, and seven of them had adjuvant chemotherapy and two had adjuvant chemoradiation.
  • All the patients in stage I survived until the period of follow-up, and their average survival time was 31.8 months.
  • One patient in stage IIC died of intestinal obstruction within 9 months from the surgery.
  • The mechanism of the malignant transformation arising in ovarian MCT is not clear, but considering the fact that 80% of MCTs are diagnosed during the reproductive age, malignant transformation seems to be related to the long-term presence of nonremoved MCT in the abdomen.
  • Accordingly, it is considered helpful for preventing and early detection of the malignant transformation to have regular ovary examination through pelvic ultrasonogram during the reproductive age.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Teratoma / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445624.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Skirnisdottir I, Nordqvist S, Sorbe B: Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past? Oncol Rep; 2005 Aug;14(2):521-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
  • External abdomino-pelvic irradiation after primary surgery in early stages of epithelial ovarian carcinoma has been used as adjuvant therapy.
  • The aims of this study were to evaluate efficacy and tolerability of abdomino-pelvic radiotherapy in ovarian carcinomas and to find predictive factors for recurrent disease.
  • From January 1979 to December 1993, 215 patients with FIGO stage IA-IIC epithelial ovarian carcinoma were treated with postoperative radiotherapy.
  • The dose of specification was 20 Gy to the upper part of the abdominal cavity and 40 Gy to the lower part of the abdomen and the pelvic region.
  • In a multivariate analysis, FIGO-stage, histopathological type and tumor grade were independent prognostic factors with recurrent-free survival as the end-point.
  • Early radiation reactions of any type were noted in 85% of the cases.
  • In conclusion, adjuvant abdomino-pelvic radiotherapy is a treatment option in early stages of ovarian carcinoma together with chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Combined Modality Therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome


27. Sun T, Feng Y, Zhu Y, Zheng Y: Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma. Chin Med J (Engl); 2000 Jul;113(7):625-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma.
  • OBJECTIVE: To investigate the optimal time of debulking in stage/II to stage IV epithelial ovarian carcinoma, considering corresponding advantages of both surgery and chemotherapy.
  • METHODS: From January 1989 to December 1996, ninety-five stage II to stage IV ovarian cancer patients were treated under two different regimens.
  • Group A-76 cases (2 cases in IIa stage, 4 cases in IIb stage, 6 cases in IIc stage, 58 cases in IIIc stage and 7 cases in IV stage) was managed according to a traditional surgery-chemotherapy regimen; and group B-19 cases (17 cases in IIIc stage and 2 cases in IV stage) was managed with a chemotherapy-surgery-chemotherapy regimen.
  • The average survival time of those with a residual focus > 2 cm was shorter than those with a residual focus < 2 cm, in both groups.
  • Sixteen out of the 51 patients with a residual focus > 2 cm had a second debulking operation, among whom 7 had preoperative chemotherapy.
  • In 9 cases without preoperative chemotherapy, the residuals were all > 2 cm.
  • The average survival time among these two groups were significantly different (P < 0.01). CONCLUSION:.
  • (1) For those patients in whom optimal debulking was clinically assessed to be possible, timely operation is mandatory. (2) For those inoperable advanced cases, chemotherapy-surgery-chemotherapy regimen is recommended. (3) For those with residuals > 2 cm and were assessed to be difficult to eradicate during second-look operation, multi-route chemotherapy (intro-arterial, intraperitoneal, and systematic) should be given before going on the second debulking operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Staging. Prognosis. Reoperation. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776033.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Fuso L, Amant F, Neven P, Berteloot P, Vergote I: Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:60-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients.
  • Single-agent gemcitabine demonstrated response rates of 11-60% in platinum/paclitaxel-resistant ovarian cancer.
  • Twenty-four patients with epithelial ovarian cancer were treated with gemcitabine 800 mg/m2 on days 1 and 8, carboplatin area under the curve 5 on day 1, and paclitaxel 175 mg/m2 over 3 h on day 1 every 3 weeks for six cycles.
  • Median age was 54 years, and FIGO stage distribution was IIC, 1 patient, III, 18, and IV, 5.
  • A total of 22 (92%) patients completed all the six planned courses of chemotherapy.
  • Overall in the 17 patients with measurable disease, the response rate at the end of the first-line chemotherapy (including interval debulking) was 94% (14 [82%] complete response and 2 [12%], partial response).
  • Using the CA125 criteria as defined by the Gynecologic Cancer Intergroup, all patients had at least a partial response prior to interval debulking, and the overall response rate of the whole first-line chemotherapy and interval debulking (n= 15) was observed in 21 out of 23 patients (91%).
  • The gemcitabine, carboplatin, paclitaxel triplet has an acceptable toxicity with high response rates as first-line therapy in advanced ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515569.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Skírnisdóttir I, Seidal T, Sorbe B: A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer; 2004 Mar-Apr;14(2):259-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
  • Epithelial ovarian carcinoma rarely occurs because of a single event.
  • Therefore, no single biological tumor factor will give accurate prognostic information for all ovarian cancer patients.
  • Because FIGO stage is included in most of the previously presented models, inaccurate surgical staging in patients with apparently early disease has been a problem.
  • In a series of 226 patients with epithelial ovarian carcinomas in FIGO stages IA-IIC, a number of clinicopathological factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to the biological factors p53 and epidermal growth factor receptor (EGFR), important regulators of the apoptosis and mitosis.
  • All patients received adjuvant radiotherapy or chemotherapy after the primary surgery.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Decision Support Techniques. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Sweden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15086725.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Varras M, Tsikini A, Polyzos D, Samara Ch, Akrivis Ch: Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature. Clin Exp Obstet Gynecol; 2004;31(1):73-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature.
  • PURPOSE: Ovarian cancer presents as an acute abdomen very rarely.
  • The purpose of the study is the description of a right ovarian malignant dysgerminoma presenting as an abdominal emergency.
  • The uterus and the left ovary had normal size and echo-texture.
  • An immediate exploratory laparotomy exposed the presence of a twisted right ovarian mass and intraperitoneal hemorrhage.
  • The intra-abdominal hemorrhage ceased when the ovarian pedicle was clamped.
  • Pathologic analysis revealed a malignant dysgerminoma of the right ovary, expanding to the mesosalpinx.
  • The patient was assigned to FIGO Stage IIC and referred for platinum-based chemotherapy.
  • CONCLUSION: Ovarian malignant dysgerminoma may present as an acute abdomen because of torsion, passive blood congestion, rupture of superficial tumoral vessels and subsequent intra-abdominal hemorrhage.
  • Ovarian dysgerminoma should be part of the differential diagnosis in a young woman with acute surgical abdomen and a solid heterogeneous pelvic mass detected by ultrasonographic scan.
  • [MeSH-major] Abdomen, Acute / etiology. Dysgerminoma / complications. Hemoperitoneum / etiology. Ovarian Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998196.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Laframboise S, Chapman W, McLaughlin J, Andrulis IL: p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J; 2000 Sep-Oct;6(5):302-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
  • PURPOSE: The investigators undertook a retrospective study to determine (1) whether p53 mutations are predictors of survival in patients with advanced epithelial ovarian cancer, (2) whether p53 status by sequencing is associated with established prognostic indicators, and (3) the agreement of results between direct sequencing of p53 mutations and immunohistochemistry.
  • MATERIAL AND METHODS: This study was retrospective review of 43 patients with advanced epithelial ovarian cancer treated with surgery and by paclitaxel-based chemotherapy.
  • Surgical stages were as follows: 5% were stage IIC, 79% were stage III, and 16% were stage IV.
  • All patients received paclitaxel-based chemotherapy.
  • Patients with stages IIC/IV had a risk of 1.7 of having a p53 mutation by sequencing; grade, histology, disease-free survival and overall survival were not predictive of p53 mutation status.
  • Histopathologic factors were not statistically associated with p53 status, but more advanced surgical stage and tumor grade were suggestive of higher rates of p53 mutations, implying more aggressive behavior.
  • Furthermore, larger randomized studies are required to elucidate the role of p53 in predicting chemoresponse in advanced epithelial ovarian cancer.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genes, p53 / genetics. Mutation. Neoplasms, Glandular and Epithelial / genetics. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cisplatin / therapeutic use. Codon. DNA Mutational Analysis. Disease-Free Survival. Exons. Female. Humans. Immunohistochemistry. Middle Aged. Paclitaxel / therapeutic use. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11079169.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Codon; 0 / Tumor Suppressor Protein p53; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Skirnisdóttir I, Sorbe B, Seidal T: The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer; 2001 Mar-Apr;11(2):119-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
  • Epithelial ovarian cancer is a heterogeneous disease and many biologic and molecular factors are important for its development and progression, including growth rate, metastatic potential, chemo- and radiosensitivity, and prognosis.
  • Even in the early stages (FIGO I-II), many questions persist about the biologic behavior, optimal treatment, and prognosis.
  • In a series of 106 patients with epithelial ovarian cancers in FIGO stages IA-IIC, a number of known prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to two important growth factor receptors for oncogenesis (HER-2/neu and EGFR).
  • A therapeutic strategy for epithelial ovarian cancer might be to decrease EGFR expression by gene therapy in combination with adjuvant radiotherapy or chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Neoplasm Staging. Ovarian Neoplasms / pathology. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Regression Analysis. Survival Analysis. Treatment Outcome


33. Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A: Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology; 2006;70(4):265-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience.
  • BACKGROUND: Young age has been reported to be a favorable prognostic factor in ovarian cancer.
  • The aim of the present study was to investigate the characteristics of ovarian cancer presenting in patients aged < or =40 and assess the prognostic significance of young age.
  • METHODS: Data from 591 consecutive ovarian cancer patients, including 37 subjects (6.3%) aged < or =40, who were treated postoperatively with platinum-based chemotherapy in our institution were retrospectively reviewed.
  • Stratified analysis showed that age < or =40 was associated with improved overall survival in the subgroups of serous histology and stage IIC-IV disease; however, multivariate analyses failed to identify age as an independent predictor of survival within either subgroup (p = 0.079 and p = 0.585, respectively).
  • [MeSH-major] Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16899981.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Historical Article; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Brown JV 3rd, Epstein HD, Mattison JN, Micha JP, Rettenmaier MA, Goldstein BH: Occult fallopian tube cancer in a patient with BRCA1 breast cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):749-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
  • Primary fallopian tube cancer is very rare form of ovarian cancer.
  • A patient with breast carcinoma was initially treated for her disease in 1994.
  • Final pathology revealed occult stage IIC fallopian tube cancer with bilateral ovarian serosal involvement.
  • Consequently, the patient was referred to gynecologic oncology and underwent a pelvic and paraaortic lymphadenectomy and laparoscopic omentectomy, followed by chemotherapy.
  • Although fallopian tube cancer is rare, women who are positive for the BRCA mutation are at greater risk for developing this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. BRCA1 Protein / analysis. Breast Neoplasms / surgery. Fallopian Tube Neoplasms / surgery. Genes, BRCA1
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Female. Germ-Line Mutation. Humans. Laparoscopy. Ovarian Neoplasms / surgery. Paclitaxel / administration & dosage. Robotics. Treatment Outcome

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971141.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Zylberberg B, Dormont D, Janklewicz S, Daraï E, Madelenat P, Antoine JM: [Secondary cytoreductions in the treatment of ovarian cancers]. Gynecol Obstet Fertil; 2000 Feb;28(2):127-36
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary cytoreductions in the treatment of ovarian cancers].
  • [Transliterated title] Cytoréductions secondaires dans le traitement des cancers de l'ovaire.
  • The aim of this study was to investigate the potential benefit of secondary cytoreductive surgery for recurrent ovarian cancer.
  • METHODS: Between 1980 and 1993, 85 patients (11 stage Ic, 4 stage IIc, 70 stage III) with an epithelial ovarian cancer were treated after initial surgery with an intraperitoneal and intravenous Cis Platin-based immunochemotherapy.
  • All 21 patients who were not reoperated died with a median survival time from recurrence of eight months (10.5 months for the patients who refused to be reoperated and seven months for the patients rejected by the surgeons) against 29 for the 20 reoperated patients (P < 0.004).
  • CONCLUSION: This series is too small to enable us to draw definitive conclusions.
  • In our opinion, secondary surgical procedure should be proposed to relapsing patients to enhance efficacy of rescue chemotherapy, which is of limited value in bulky tumors.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Reoperation / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758587.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Smaldone GM, Richard SD, Edwards RP: Pregnancy outcomes after conservative surgical management of ovarian neoplasms treated at a single institution. Int J Gynecol Cancer; 2010 Aug;20(6):926-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcomes after conservative surgical management of ovarian neoplasms treated at a single institution.
  • HYPOTHESIS: Conservative surgical management of ovarian neoplasms can result in favorable oncologic and obstetric outcomes.
  • METHODS: All reproductive-age women (18-45 years old) with stage IA to stage IIC ovarian neoplasms (N = 161) were retrospectively identified from a single institution's tumor registry between 1990 and 2007.
  • Operative, pathological, outpatient, and delivery records were reviewed to confirm histological findings, stage, extent of surgical resection, adjuvant treatment, oncologic outcomes, and pregnancy outcomes.
  • RESULTS: Women who underwent conservative surgical management for ovarian neoplasms (n = 61 [37.9%]) were identified, including those with low malignant potential (LMP, n = 36), epithelial (n = 12), germ cell (n = 6), and sex cord (n = 7) tumors.
  • Of those receiving adjuvant chemotherapy (n = 8), 12.5% were able to conceive after their treatment and with no reported congenital anomalies.
  • Pregnancy after a diagnosis of ovarian neoplasm did not impact disease recurrence (0% vs 7.7%, P = 0.56) or survival (100% vs 100%, P = 1.0).
  • CONCLUSIONS: Conservative surgery may be an acceptable option for reproductive-age women with early-stage ovarian neoplasms.
  • We report pregnancy and oncologic outcomes for a cohort of women managed conservatively for LMP, epithelial, germ cell, and sex cord ovarian neoplasms.
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovariectomy / methods. Pregnancy Complications, Neoplastic / surgery. Pregnancy Outcome
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Pregnancy. Pregnancy Rate / trends. Registries. Retrospective Studies. Risk Assessment. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683397.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Mandić A, Nincić D, Vujkov T: [Ovarian epithelial carcinoma--a malignant disease sparing no age group]. Med Pregl; 2003 Mar-Apr;56(3-4):157-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian epithelial carcinoma--a malignant disease sparing no age group].
  • INTRODUCTION: Ovarian epithelial carcinoma is one of the most common gynecologic malignancies and the fifth most frequent cause of cancer death in women.
  • Ovarian cancer affects women 65 years of age and older more frequently than younger women.
  • MATERIAL AND METHODS: Four young patients with ovarian epithelial carcinoma were treated at the Institute of Oncology in Sremska Kamenica, Serbia and Montenegro, in the period 1981-2000.
  • The stage of the disease was established using International Federation of Gynecology-Obstetrics (FIGO) Calssification.
  • Spread of the disease dictated the extent of operation and post-operative chemotherapy.
  • RESULTS: The first two patients underwent unilateral adnexectomy as initial treatment.
  • Final histopathological examination revealed an epithelial ovarian carcinoma, stage IIIa and IIb.
  • Total hysterectomy with unilateral adnexectomy and total omentectomy were performed in both patients as second treatment with chemotherapy, according to the Cisplatin/Carboplatin and Cyclophos-phamide (CP) protocol following surgery.
  • Another two patients underwent total hysterectomy with bilateral adnexectomy and total omentectomy as initial treatment with chemotherapy, CP protocol, following surgery.
  • Both patients had stage IIc.
  • Despite treatment, in two patients with stage IIIa and IIc, metastases were diagnosed.
  • DISCUSSION: Ovarian carcinomas are difficult to diagnose at early stage.
  • Histologic confirmation of the diagnosis, surgical staging, and aggressive surgical debulking, when possible, are all part of the initial evaluation and treatment.
  • In most cases, surgery is followed by chemotherapy.
  • Our study included 4 patients, medium age 17.3, with epithelial ovarian carcinoma which warns us to think twice when we get an adolescent patient with an adnexal mass.
  • CONCLUSION: Advancing age, the major risk factor for development of ovarian carcinoma is, of course, unalterable.
  • We investigated 4 patients medium age 17.3 years, with epithelial ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12899081.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  •  go-up   go-down






Advertisement